_id
691483f4ccc777a4e85d94b5
Ticker
NRXBF
Name
NRXBF
Exchange
OTCQB
Address
1 Adelaide Street East, Toronto, ON, Canada, M5C 2V9
Country
USA
Sector
Healthcare
Industry
Biotechnology
Currency
USD
Website
https://nurexone.com
Description
NurExone Biologic Inc., a pharmaceutical technology company, develops a platform for biologically guided exosome-based therapies for the treatment of central nervous system injuries. It develops and commercializes the ExoTherapy platform for production of exosome-loaded nanodrugs. The company is also developing an off-the-shelf, non-invasive, and novel treatment for the reversal or reduction of paralysis caused by spinal cord injury using membrane-bound extracellular vesicles technology, as well as to treat traumatic brain injuries and other neurological conditions. Its technology includes ExoPTEN for the treatment of acute spinal cord injury and glaucoma; and Exosomes as a drug delivery system for regeneration and healing of specific tissues. The company was founded in 2020 and is based in Toronto, Canada.
Last Close
0.4821
Volume
6000
Current Price
0.4679
Change
-0.0068
Last Updated
2026-01-05T11:40:36.361Z
Image
data:image/webp;base64,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
Ipo Date
-
Market Cap
44016292
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
-
Sentiment Sources
0
Current Quarter
2025-09-30
Revenue
0
Cost Of Revenue
-
Gross Profit
-
Operating Expenses
1466000
Operating Income
-1466000
Interest Expense
20000
Pretax Income
-1465000
Net Income
-1465000
Eps
-0.017766352335629558
Dividends Per Share
-
Shares Outstanding
90681345
Income Tax Expense
-
EBITDA
-
Operating Margin
-
Total Other Income Expense Net
-
Cash
983000
Short Term Investments
-
Receivables
-
Inventories
-
Total Current Assets
1146000
Property Plant Equipment
882000
Total Assets
2646000
Payables
-
Short Term Debt
-
Long Term Debt
-
Total Liabilities
1189000
Equity
1457000
Bs_currency_symbol
USD
Depreciation
47000
Change In Working Capital
-195000
Cash From Operations
-1284000
Capital Expenditures
12000
Cash From Investing
-
Cash From Financing
1062000
Net Change In Cash
-245000
Cf_currency_symbol
USD
PE
-
PB
26.48090647597804
ROE
-100.5490734385724
ROA
-55.366591080876795
FCF
-1296000
Fcf Percent
-
Piotroski FScore
1
Health Score
31
Deep Value Investing Score
2
Defensive Investing Score
4.5
Dividend Investing Score
1.5
Economic Moat Investing Score
3.3
Garp Investing Score
1.5
Growth Investing Score
0.5
Momentum Investing Score
2
Net Net Investing Score
2.5
Quality Investing Score
2
Value Investing Score
2.5
Quarters > 0 > quarter
2025-09-30
Quarters > 0 > income Statement > revenue
0
Quarters > 0 > income Statement > cost Of Revenue
-
Quarters > 0 > income Statement > gross Profit
-
Quarters > 0 > income Statement > operating Expenses
1466000
Quarters > 0 > income Statement > operating Income
-1466000
Quarters > 0 > income Statement > interest Expense
20000
Quarters > 0 > income Statement > pretax Income
-1465000
Quarters > 0 > income Statement > net Income
-1465000
Quarters > 0 > income Statement > eps
-0.017766352335629558
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
82459245
Quarters > 0 > income Statement > income Tax Expense
-
Quarters > 0 > income Statement > EBITDA
-
Quarters > 0 > income Statement > operating Margin
-
Quarters > 0 > income Statement > total Other Income Expense Net
-
Quarters > 0 > income Statement > currency_symbol
USD
Quarters > 0 > balance Sheet > cash
983000
Quarters > 0 > balance Sheet > short Term Investments
-
Quarters > 0 > balance Sheet > receivables
-
Quarters > 0 > balance Sheet > inventories
-
Quarters > 0 > balance Sheet > total Current Assets
1146000
Quarters > 0 > balance Sheet > property Plant Equipment
882000
Quarters > 0 > balance Sheet > total Assets
2646000
Quarters > 0 > balance Sheet > payables
-
Quarters > 0 > balance Sheet > short Term Debt
-
Quarters > 0 > balance Sheet > long Term Debt
-
Quarters > 0 > balance Sheet > total Liabilities
1189000
Quarters > 0 > balance Sheet > equity
1457000
Quarters > 0 > balance Sheet > currency_symbol
USD
Quarters > 0 > cash Flow > net Income
-1465000
Quarters > 0 > cash Flow > depreciation
47000
Quarters > 0 > cash Flow > change In Working Capital
-195000
Quarters > 0 > cash Flow > cash From Operations
-1284000
Quarters > 0 > cash Flow > capital Expenditures
12000
Quarters > 0 > cash Flow > cash From Investing
-
Quarters > 0 > cash Flow > cash From Financing
1062000
Quarters > 0 > cash Flow > net Change In Cash
-245000
Quarters > 0 > cash Flow > currency_symbol
USD
Quarters > 0 > ratios > PE
-0.017766352335629558
Quarters > 0 > ratios > PB
26.48090647597804
Quarters > 0 > ratios > ROE
-100.5490734385724
Quarters > 0 > ratios > ROA
-55.366591080876795
Quarters > 0 > ratios > FCF
-1296000
Quarters > 0 > ratios > Piotroski FScore
1
Quarters > 0 > ratios > fcf Percent
-
Quarters > 0 > health Score
31
Quarters > 1 > quarter
2025-06-30
Quarters > 1 > income Statement > revenue
0
Quarters > 1 > income Statement > cost Of Revenue
-
Quarters > 1 > income Statement > gross Profit
-
Quarters > 1 > income Statement > operating Expenses
1822000
Quarters > 1 > income Statement > operating Income
-1822000
Quarters > 1 > income Statement > interest Expense
33000
Quarters > 1 > income Statement > pretax Income
-1846000
Quarters > 1 > income Statement > net Income
-1846000
Quarters > 1 > income Statement > eps
-0.02479027807480527
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
74464675
Quarters > 1 > income Statement > income Tax Expense
-
Quarters > 1 > income Statement > EBITDA
-
Quarters > 1 > income Statement > operating Margin
-
Quarters > 1 > income Statement > total Other Income Expense Net
-
Quarters > 1 > income Statement > currency_symbol
USD
Quarters > 1 > balance Sheet > cash
1228000
Quarters > 1 > balance Sheet > short Term Investments
-
Quarters > 1 > balance Sheet > receivables
-
Quarters > 1 > balance Sheet > inventories
-
Quarters > 1 > balance Sheet > total Current Assets
1953000
Quarters > 1 > balance Sheet > property Plant Equipment
911000
Quarters > 1 > balance Sheet > total Assets
2864000
Quarters > 1 > balance Sheet > payables
-
Quarters > 1 > balance Sheet > short Term Debt
-
Quarters > 1 > balance Sheet > long Term Debt
-
Quarters > 1 > balance Sheet > total Liabilities
1332000
Quarters > 1 > balance Sheet > equity
1532000
Quarters > 1 > balance Sheet > currency_symbol
USD
Quarters > 1 > cash Flow > net Income
-1846000
Quarters > 1 > cash Flow > depreciation
42000
Quarters > 1 > cash Flow > change In Working Capital
424000
Quarters > 1 > cash Flow > cash From Operations
-1067000
Quarters > 1 > cash Flow > capital Expenditures
2000
Quarters > 1 > cash Flow > cash From Investing
-
Quarters > 1 > cash Flow > cash From Financing
1590000
Quarters > 1 > cash Flow > net Change In Cash
640000
Quarters > 1 > cash Flow > currency_symbol
USD
Quarters > 1 > ratios > PE
-0.02479027807480527
Quarters > 1 > ratios > PB
22.742833833224545
Quarters > 1 > ratios > ROE
-120.49608355091384
Quarters > 1 > ratios > ROA
-64.45530726256983
Quarters > 1 > ratios > FCF
-1069000
Quarters > 1 > ratios > Piotroski FScore
1
Quarters > 1 > ratios > fcf Percent
-
Quarters > 1 > health Score
31
Quarters > 2 > quarter
2025-03-31
Quarters > 2 > income Statement > revenue
0
Quarters > 2 > income Statement > cost Of Revenue
-
Quarters > 2 > income Statement > gross Profit
-
Quarters > 2 > income Statement > operating Expenses
1700000
Quarters > 2 > income Statement > operating Income
-1700000
Quarters > 2 > income Statement > interest Expense
11000
Quarters > 2 > income Statement > pretax Income
-1678000
Quarters > 2 > income Statement > net Income
-1678000
Quarters > 2 > income Statement > eps
-0.022534174761388536
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
74464675
Quarters > 2 > income Statement > income Tax Expense
-
Quarters > 2 > income Statement > EBITDA
-
Quarters > 2 > income Statement > operating Margin
-
Quarters > 2 > income Statement > total Other Income Expense Net
-
Quarters > 2 > income Statement > currency_symbol
USD
Quarters > 2 > balance Sheet > cash
588000
Quarters > 2 > balance Sheet > short Term Investments
-
Quarters > 2 > balance Sheet > receivables
-
Quarters > 2 > balance Sheet > inventories
-
Quarters > 2 > balance Sheet > total Current Assets
1364000
Quarters > 2 > balance Sheet > property Plant Equipment
776000
Quarters > 2 > balance Sheet > total Assets
2140000
Quarters > 2 > balance Sheet > payables
-
Quarters > 2 > balance Sheet > short Term Debt
-
Quarters > 2 > balance Sheet > long Term Debt
-
Quarters > 2 > balance Sheet > total Liabilities
824000
Quarters > 2 > balance Sheet > equity
1316000
Quarters > 2 > balance Sheet > currency_symbol
USD
Quarters > 2 > cash Flow > net Income
-1678000
Quarters > 2 > cash Flow > depreciation
43000
Quarters > 2 > cash Flow > change In Working Capital
336000
Quarters > 2 > cash Flow > cash From Operations
-986000
Quarters > 2 > cash Flow > capital Expenditures
32000
Quarters > 2 > cash Flow > cash From Investing
-
Quarters > 2 > cash Flow > cash From Financing
910000
Quarters > 2 > cash Flow > net Change In Cash
-112000
Quarters > 2 > cash Flow > currency_symbol
USD
Quarters > 2 > ratios > PE
-0.022534174761388536
Quarters > 2 > ratios > PB
26.475700176671733
Quarters > 2 > ratios > ROE
-127.50759878419453
Quarters > 2 > ratios > ROA
-78.41121495327103
Quarters > 2 > ratios > FCF
-1018000
Quarters > 2 > ratios > Piotroski FScore
1
Quarters > 2 > ratios > fcf Percent
-
Quarters > 2 > health Score
31
Quarters > 3 > quarter
2024-12-31
Quarters > 3 > income Statement > revenue
0
Quarters > 3 > income Statement > cost Of Revenue
-
Quarters > 3 > income Statement > gross Profit
-
Quarters > 3 > income Statement > operating Expenses
1484000
Quarters > 3 > income Statement > operating Income
-1484000
Quarters > 3 > income Statement > interest Expense
1000
Quarters > 3 > income Statement > pretax Income
-1546000
Quarters > 3 > income Statement > net Income
-1546000
Quarters > 3 > income Statement > eps
-0.021752099844445753
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
71073598
Quarters > 3 > income Statement > income Tax Expense
-
Quarters > 3 > income Statement > EBITDA
-
Quarters > 3 > income Statement > operating Margin
-
Quarters > 3 > income Statement > total Other Income Expense Net
-
Quarters > 3 > income Statement > currency_symbol
USD
Quarters > 3 > balance Sheet > cash
700000
Quarters > 3 > balance Sheet > short Term Investments
-
Quarters > 3 > balance Sheet > receivables
-
Quarters > 3 > balance Sheet > inventories
-
Quarters > 3 > balance Sheet > total Current Assets
1634000
Quarters > 3 > balance Sheet > property Plant Equipment
807000
Quarters > 3 > balance Sheet > total Assets
2441000
Quarters > 3 > balance Sheet > payables
-
Quarters > 3 > balance Sheet > short Term Debt
-
Quarters > 3 > balance Sheet > long Term Debt
-
Quarters > 3 > balance Sheet > total Liabilities
680000
Quarters > 3 > balance Sheet > equity
1761000
Quarters > 3 > balance Sheet > currency_symbol
USD
Quarters > 3 > cash Flow > net Income
-1546000
Quarters > 3 > cash Flow > depreciation
39000
Quarters > 3 > cash Flow > change In Working Capital
-561000
Quarters > 3 > cash Flow > cash From Operations
-1735000
Quarters > 3 > cash Flow > capital Expenditures
46000
Quarters > 3 > cash Flow > cash From Investing
-
Quarters > 3 > cash Flow > cash From Financing
177000
Quarters > 3 > cash Flow > net Change In Cash
-1823000
Quarters > 3 > cash Flow > currency_symbol
USD
Quarters > 3 > ratios > PE
-0.021752099844445753
Quarters > 3 > ratios > PB
18.8843478161272
Quarters > 3 > ratios > ROE
-87.79102782509938
Quarters > 3 > ratios > ROA
-63.33469889389595
Quarters > 3 > ratios > FCF
-1781000
Quarters > 3 > ratios > Piotroski FScore
0
Quarters > 3 > ratios > fcf Percent
-
Quarters > 3 > health Score
34
Annuals > 0 > quarter
2024-12-31
Annuals > 0 > income Statement > revenue
0
Annuals > 0 > income Statement > cost Of Revenue
-
Annuals > 0 > income Statement > gross Profit
-
Annuals > 0 > income Statement > operating Expenses
5009000
Annuals > 0 > income Statement > operating Income
-5009000
Annuals > 0 > income Statement > interest Expense
16000
Annuals > 0 > income Statement > pretax Income
-5043000
Annuals > 0 > income Statement > net Income
-5043000
Annuals > 0 > income Statement > eps
-0.07095461805662351
Annuals > 0 > income Statement > dividends Per Share
-
Annuals > 0 > income Statement > shares Outstanding
71073598
Annuals > 0 > income Statement > income Tax Expense
-
Annuals > 0 > income Statement > EBITDA
-
Annuals > 0 > income Statement > operating Margin
-
Annuals > 0 > income Statement > total Other Income Expense Net
-65000
Annuals > 0 > income Statement > currency_symbol
USD
Annuals > 0 > balance Sheet > cash
700000
Annuals > 0 > balance Sheet > short Term Investments
-
Annuals > 0 > balance Sheet > receivables
-
Annuals > 0 > balance Sheet > inventories
-
Annuals > 0 > balance Sheet > total Current Assets
1634000
Annuals > 0 > balance Sheet > property Plant Equipment
807000
Annuals > 0 > balance Sheet > total Assets
2441000
Annuals > 0 > balance Sheet > payables
-
Annuals > 0 > balance Sheet > short Term Debt
-
Annuals > 0 > balance Sheet > long Term Debt
-
Annuals > 0 > balance Sheet > total Liabilities
680000
Annuals > 0 > balance Sheet > equity
1761000
Annuals > 0 > balance Sheet > currency_symbol
USD
Annuals > 0 > cash Flow > net Income
-5043000
Annuals > 0 > cash Flow > depreciation
85000
Annuals > 0 > cash Flow > change In Working Capital
-923000
Annuals > 0 > cash Flow > cash From Operations
-4888000
Annuals > 0 > cash Flow > capital Expenditures
649000
Annuals > 0 > cash Flow > cash From Investing
-
Annuals > 0 > cash Flow > cash From Financing
5878000
Annuals > 0 > cash Flow > net Change In Cash
159000
Annuals > 0 > cash Flow > currency_symbol
USD
Annuals > 0 > ratios > PE
-0.07095461805662351
Annuals > 0 > ratios > PB
19.457456897103917
Annuals > 0 > ratios > ROE
-286.37137989778535
Annuals > 0 > ratios > ROA
-206.59565751741093
Annuals > 0 > ratios > FCF
-5537000
Annuals > 0 > ratios > Piotroski FScore
0
Annuals > 0 > ratios > fcf Percent
-
Annuals > 0 > health Score
26
Annuals > 1 > quarter
2023-12-31
Annuals > 1 > income Statement > revenue
0
Annuals > 1 > income Statement > cost Of Revenue
-
Annuals > 1 > income Statement > gross Profit
-
Annuals > 1 > income Statement > operating Expenses
3657000
Annuals > 1 > income Statement > operating Income
-3657000
Annuals > 1 > income Statement > interest Expense
3000
Annuals > 1 > income Statement > pretax Income
-3639000
Annuals > 1 > income Statement > net Income
-3639000
Annuals > 1 > income Statement > eps
-0.07542014711094515
Annuals > 1 > income Statement > dividends Per Share
-
Annuals > 1 > income Statement > shares Outstanding
48249707
Annuals > 1 > income Statement > income Tax Expense
-
Annuals > 1 > income Statement > EBITDA
-
Annuals > 1 > income Statement > operating Margin
-
Annuals > 1 > income Statement > total Other Income Expense Net
-24000
Annuals > 1 > income Statement > currency_symbol
USD
Annuals > 1 > balance Sheet > cash
541000
Annuals > 1 > balance Sheet > short Term Investments
-
Annuals > 1 > balance Sheet > receivables
-
Annuals > 1 > balance Sheet > inventories
-
Annuals > 1 > balance Sheet > total Current Assets
1982000
Annuals > 1 > balance Sheet > property Plant Equipment
188000
Annuals > 1 > balance Sheet > total Assets
2170000
Annuals > 1 > balance Sheet > payables
-
Annuals > 1 > balance Sheet > short Term Debt
-
Annuals > 1 > balance Sheet > long Term Debt
-
Annuals > 1 > balance Sheet > total Liabilities
1981000
Annuals > 1 > balance Sheet > equity
189000
Annuals > 1 > balance Sheet > currency_symbol
USD
Annuals > 1 > cash Flow > net Income
-3639000
Annuals > 1 > cash Flow > depreciation
33000
Annuals > 1 > cash Flow > change In Working Capital
4000
Annuals > 1 > cash Flow > cash From Operations
-2941000
Annuals > 1 > cash Flow > capital Expenditures
120000
Annuals > 1 > cash Flow > cash From Investing
-
Annuals > 1 > cash Flow > cash From Financing
1132000
Annuals > 1 > cash Flow > net Change In Cash
-1922000
Annuals > 1 > cash Flow > currency_symbol
USD
Annuals > 1 > ratios > PE
-0.07542014711094515
Annuals > 1 > ratios > PB
123.07504626825397
Annuals > 1 > ratios > ROE
-1925.3968253968253
Annuals > 1 > ratios > ROA
-167.69585253456222
Annuals > 1 > ratios > FCF
-3061000
Annuals > 1 > ratios > Piotroski FScore
0
Annuals > 1 > ratios > fcf Percent
-
Annuals > 1 > health Score
8
Annuals > 2 > quarter
2022-12-31
Annuals > 2 > income Statement > revenue
0
Annuals > 2 > income Statement > cost Of Revenue
-
Annuals > 2 > income Statement > gross Profit
-
Annuals > 2 > income Statement > operating Expenses
5541000
Annuals > 2 > income Statement > operating Income
-5541000
Annuals > 2 > income Statement > interest Expense
33000
Annuals > 2 > income Statement > pretax Income
-8169000
Annuals > 2 > income Statement > net Income
-8169000
Annuals > 2 > income Statement > eps
-0.19061882819332973
Annuals > 2 > income Statement > dividends Per Share
-
Annuals > 2 > income Statement > shares Outstanding
42855158
Annuals > 2 > income Statement > income Tax Expense
-
Annuals > 2 > income Statement > EBITDA
-
Annuals > 2 > income Statement > operating Margin
-
Annuals > 2 > income Statement > total Other Income Expense Net
-2610000
Annuals > 2 > income Statement > currency_symbol
USD
Annuals > 2 > balance Sheet > cash
2463000
Annuals > 2 > balance Sheet > short Term Investments
-
Annuals > 2 > balance Sheet > receivables
-
Annuals > 2 > balance Sheet > inventories
-
Annuals > 2 > balance Sheet > total Current Assets
2692000
Annuals > 2 > balance Sheet > property Plant Equipment
101000
Annuals > 2 > balance Sheet > total Assets
2794000
Annuals > 2 > balance Sheet > payables
-
Annuals > 2 > balance Sheet > short Term Debt
-
Annuals > 2 > balance Sheet > long Term Debt
-
Annuals > 2 > balance Sheet > total Liabilities
698000
Annuals > 2 > balance Sheet > equity
2096000
Annuals > 2 > balance Sheet > currency_symbol
USD
Annuals > 2 > cash Flow > net Income
-8169000
Annuals > 2 > cash Flow > depreciation
6000
Annuals > 2 > cash Flow > change In Working Capital
237000
Annuals > 2 > cash Flow > cash From Operations
-3848000
Annuals > 2 > cash Flow > capital Expenditures
52000
Annuals > 2 > cash Flow > cash From Investing
-
Annuals > 2 > cash Flow > cash From Financing
4295000
Annuals > 2 > cash Flow > net Change In Cash
249000
Annuals > 2 > cash Flow > currency_symbol
USD
Annuals > 2 > ratios > PE
-0.19061882819332973
Annuals > 2 > ratios > PB
9.857095263263357
Annuals > 2 > ratios > ROE
-389.74236641221376
Annuals > 2 > ratios > ROA
-292.3765211166786
Annuals > 2 > ratios > FCF
-3900000
Annuals > 2 > ratios > Piotroski FScore
0
Annuals > 2 > ratios > fcf Percent
-
Annuals > 2 > health Score
26
Annuals > 3 > quarter
2021-12-31
Annuals > 3 > income Statement > revenue
0
Annuals > 3 > income Statement > cost Of Revenue
-
Annuals > 3 > income Statement > gross Profit
-
Annuals > 3 > income Statement > operating Expenses
1713000
Annuals > 3 > income Statement > operating Income
-1713000
Annuals > 3 > income Statement > interest Expense
12000
Annuals > 3 > income Statement > pretax Income
-1647000
Annuals > 3 > income Statement > net Income
-1647000
Annuals > 3 > income Statement > eps
-0.03843177990383328
Annuals > 3 > income Statement > dividends Per Share
-
Annuals > 3 > income Statement > shares Outstanding
42855158
Annuals > 3 > income Statement > income Tax Expense
-
Annuals > 3 > income Statement > EBITDA
-
Annuals > 3 > income Statement > operating Margin
-
Annuals > 3 > income Statement > total Other Income Expense Net
79000
Annuals > 3 > income Statement > currency_symbol
USD
Annuals > 3 > balance Sheet > cash
2214000
Annuals > 3 > balance Sheet > short Term Investments
-
Annuals > 3 > balance Sheet > receivables
-
Annuals > 3 > balance Sheet > inventories
-
Annuals > 3 > balance Sheet > total Current Assets
2836000
Annuals > 3 > balance Sheet > property Plant Equipment
0
Annuals > 3 > balance Sheet > total Assets
2836000
Annuals > 3 > balance Sheet > payables
-
Annuals > 3 > balance Sheet > short Term Debt
-
Annuals > 3 > balance Sheet > long Term Debt
-
Annuals > 3 > balance Sheet > total Liabilities
1659000
Annuals > 3 > balance Sheet > equity
1177000
Annuals > 3 > balance Sheet > currency_symbol
USD
Annuals > 3 > cash Flow > net Income
-1647000
Annuals > 3 > cash Flow > depreciation
0
Annuals > 3 > cash Flow > change In Working Capital
289000
Annuals > 3 > cash Flow > cash From Operations
-1232000
Annuals > 3 > cash Flow > capital Expenditures
0
Annuals > 3 > cash Flow > cash From Investing
-
Annuals > 3 > cash Flow > cash From Financing
3463000
Annuals > 3 > cash Flow > net Change In Cash
2212000
Annuals > 3 > cash Flow > currency_symbol
USD
Annuals > 3 > ratios > PE
-0.03843177990383328
Annuals > 3 > ratios > PB
17.55350184519966
Annuals > 3 > ratios > ROE
-139.9320305862362
Annuals > 3 > ratios > ROA
-58.074753173483785
Annuals > 3 > ratios > FCF
-1232000
Annuals > 3 > ratios > Piotroski FScore
0
Annuals > 3 > ratios > fcf Percent
-
Annuals > 3 > health Score
16
Valuation > metrics > PE
-0.017766352335629558
Valuation > metrics > PB
26.48090647597804
Valuation > final Score
20
Valuation > verdict
782.7% Overvalued
Profitability > metrics > ROE
-100.5490734385724
Profitability > metrics > ROA
-127.83595113438044
Profitability > final Score
15
Profitability > verdict
Weak
Risk > metrics > Debt Equity
0.8160603980782429
Risk > metrics > Interest Coverage
-73.3
Risk > final Score
-245
Risk > verdict
High
Liquidity > final Score
50
Liquidity > verdict
Weak
Prev Valuations > 0
20
Prev Valuations > 1
20
Prev Valuations > 2
20
Prev Profitabilities > 0
15
Prev Profitabilities > 1
15
Prev Profitabilities > 2
15
Prev Risks > 0
-173
Prev Risks > 1
-570
Prev Risks > 2
-5876
Prev Liquidities > 0
50
Prev Liquidities > 1
50
Prev Liquidities > 2
50
Updated At
2026-01-20T22:18:19.443Z
Earnings History > 0 > period
2025-09-30
Earnings History > 0 > report Date
2025-09-30
Earnings History > 0 > date
2025-09-30
Earnings History > 0 > before After Market
-
Earnings History > 0 > currency
-
Earnings History > 0 > eps Actual
-0.02
Earnings History > 0 > eps Estimate
-0.02
Earnings History > 0 > eps Difference
0
Earnings History > 0 > surprise Percent
0
Earnings History > 1 > period
2025-06-30
Earnings History > 1 > report Date
2025-06-30
Earnings History > 1 > date
2025-06-30
Earnings History > 1 > before After Market
-
Earnings History > 1 > currency
-
Earnings History > 1 > eps Actual
-0.024
Earnings History > 1 > eps Estimate
-0.02
Earnings History > 1 > eps Difference
-0.004
Earnings History > 1 > surprise Percent
-20
Earnings History > 2 > period
2025-03-31
Earnings History > 2 > report Date
2025-03-31
Earnings History > 2 > date
2025-03-31
Earnings History > 2 > before After Market
-
Earnings History > 2 > currency
-
Earnings History > 2 > eps Actual
-0.023
Earnings History > 2 > eps Estimate
-0.02
Earnings History > 2 > eps Difference
-0.003
Earnings History > 2 > surprise Percent
-15
Earnings History > 3 > period
2024-12-31
Earnings History > 3 > report Date
2024-12-31
Earnings History > 3 > date
2024-12-31
Earnings History > 3 > before After Market
-
Earnings History > 3 > currency
-
Earnings History > 3 > eps Actual
-0.019
Earnings History > 3 > eps Estimate
-0.02
Earnings History > 3 > eps Difference
0.001
Earnings History > 3 > surprise Percent
5
Earnings History > 4 > period
2024-09-30
Earnings History > 4 > report Date
2024-09-30
Earnings History > 4 > date
2024-09-30
Earnings History > 4 > before After Market
-
Earnings History > 4 > currency
USD
Earnings History > 4 > eps Actual
-0.02
Earnings History > 4 > eps Estimate
-0.03
Earnings History > 4 > eps Difference
0.01
Earnings History > 4 > surprise Percent
33.3333
Earnings History > 5 > period
2024-06-30
Earnings History > 5 > report Date
2024-06-30
Earnings History > 5 > date
2024-06-30
Earnings History > 5 > before After Market
-
Earnings History > 5 > currency
USD
Earnings History > 5 > eps Actual
-0.0215
Earnings History > 5 > eps Estimate
-
Earnings History > 5 > eps Difference
0
Earnings History > 5 > surprise Percent
-
Earnings History > 6 > period
2024-03-31
Earnings History > 6 > report Date
2024-03-31
Earnings History > 6 > date
2024-03-31
Earnings History > 6 > before After Market
-
Earnings History > 6 > currency
USD
Earnings History > 6 > eps Actual
-0.0163
Earnings History > 6 > eps Estimate
-0.02
Earnings History > 6 > eps Difference
0.0037
Earnings History > 6 > surprise Percent
18.5
Earnings History > 7 > period
2023-12-31
Earnings History > 7 > report Date
2023-12-31
Earnings History > 7 > date
2023-12-31
Earnings History > 7 > before After Market
-
Earnings History > 7 > currency
USD
Earnings History > 7 > eps Actual
-0.0165
Earnings History > 7 > eps Estimate
-
Earnings History > 7 > eps Difference
0
Earnings History > 7 > surprise Percent
-
Earnings History > 8 > period
2023-06-30
Earnings History > 8 > report Date
2023-08-28
Earnings History > 8 > date
2023-06-30
Earnings History > 8 > before After Market
BeforeMarket
Earnings History > 8 > currency
USD
Earnings History > 8 > eps Actual
-0.02
Earnings History > 8 > eps Estimate
-0.02
Earnings History > 8 > eps Difference
0
Earnings History > 8 > surprise Percent
0
NurExone Biologic Inc., a pharmaceutical technology company, develops a platform for biologically guided exosome-based therapies for the treatment of central nervous system injuries. It develops and commercializes the ExoTherapy platform for production of exosome-loaded nanodrugs. The company is also developing an off-the-shelf, non-invasive, and novel treatment for the reversal or reduction of paralysis caused by spinal cord injury using membrane-bound extracellular vesicles technology, as well as to treat traumatic brain injuries and other neurological conditions. Its technology includes ExoPTEN for the treatment of acute spinal cord injury and glaucoma; and Exosomes as a drug delivery system for regeneration and healing of specific tissues. The company was founded in 2020 and is based in Toronto, Canada.
Stock Price
$0.00
decrease compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/A(Last Updated 2025-09-30)
Health Score
Price to Book Ratio (P/B)
-
Very High
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Debt to Equity
-
Low
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 0.00% of the total shares of NRXBF
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
Date
—
EPS Estimate
—
Date
2025-09-30
EPS Actual
-0.02
EPS Estimate
-0.02
EPS Difference
0
Surprise Percent
0%
(Last Updated 2025-09-30)
(Last Updated 2025-09-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-09-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2025-09-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.